SelectQuote, Inc. Q3 2026 Earnings Call Summary

SelectQuote, Inc. Q3 2026 Earnings Call Summary - Moby

Strategic Performance Drivers

Performance was anchored by a 1% improvement in Senior agent productivity and a 14% reduction in marketing spend per policy over a two-year period, despite a volatile Medicare Advantage environment. Management attributed the $14 million positive adjustment to commissions receivable to increased visibility into policyholder retention, validating the long-term value of the $1 billion balance sheet asset. The Healthcare Services segment saw a 64% increase in prescriptions shipped over two years, driven by the maturation of the SelectRx membership base and improved utilization. Operational efficiency is being prioritized through the Olathe, Kansas distribution facility, which currently delivers 30% higher efficiency than legacy locations despite running at less than 50% capacity. The company launched 'SelectQuote Local,' a franchise model designed to expand market reach via a fee-based arrangement with minimal capital investment. Management explicitly addressed the 'dislocated' equity valuation, noting that the Medicare Advantage commissions receivable alone is nearly five times the company's current market capitalization.

Strategic Outlook and Fiscal 2027 Targets

Fiscal 2027 is positioned as a pivot point for accelerated cash flow growth, supported by the full integration of a proprietary pharmacy management system to scale the Olathe facility. Management anticipates continued market discipline and potential disruption in the Medicare Advantage ecosystem through 2027 as carriers prioritize margin recovery over growth. The company reaffirmed its commitment to maintaining its NYSE listing and is evaluating capital market transactions, including further securitizations or potential industry consolidation. SelectRx is expected to reach a $40 million to $50 million EBITDA run rate in the near term as membership seasoning and operational leverage compound. Guidance for the remainder of fiscal 2026 remains unchanged to account for potential timing shifts in policy approvals that may have pulled forward volume from the fourth quarter.

Regulatory and Structural Impacts

The Inflation Reduction Act (IRA) caused a sequential revenue decline in Healthcare Services due to price caps on 10 high-priced drugs, though the EBITDA impact was limited to the low single-digit millions and was fully accounted for in the company's original forecast. A $13 million refund from drug manufacturers flowed through the cost of goods sold, partially offsetting the top-line impact of the IRA price changes. The company secured a multi-year agreement with its largest PBM partner, stabilizing reimbursement rates following earlier volatility in the fiscal year. Management highlighted a 33% recapture rate over the last two disruptive Medicare seasons as a key indicator of the model's resilience against industry-wide churn.

Story Continues

Q&A Session Summary

PBM reimbursement environment and IRA impact on SelectRx

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management confirmed the reimbursement environment is now stable following the resolution of earlier rate challenges and the signing of a multi-year PBM contract. The sequential revenue drop in SelectRx was primarily a 'geography change' in accounting caused by the IRA, with drug manufacturer refunds mitigating the bottom-line impact.

Visibility into Medicare Advantage ecosystem recovery

While medical cost trends are easing slightly, management remains cautious, expecting carriers to maintain discipline through 2027 before a potential return to targeted growth in 2028. The company views potential plan disruption as a manageable dynamic given their 15-year history of navigating Medicare cycles.

Strategies to remedy equity valuation disconnect

Beyond operational execution, management is exploring securitization of receivables and potential M&A or consolidation opportunities. The executive team emphasized that the company's diversification and cash flow durability make it a likely 'survivor' in a consolidating market.

Scaling the Olathe distribution facility and pharmacy management system

The new proprietary pharmacy management system is currently in the testing phase with the first patients successfully processed. Transitioning volume to the Olathe facility is expected to improve margins across all locations by reducing the need for expensive late-night shifts at legacy sites.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

View Comments